Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
- Conditions
- Psychosocial Effects of Cancer and Its TreatmentBreast Cancer
- Registration Number
- NCT00068328
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Brief Summary
RATIONALE: Studying how older women make treatment decisions and how these decisions affect the outcome of treatment may help doctors plan more effective treatments and improve patient quality of life.
PURPOSE: This clinical trial is studying how a patient's treatment preferences and decisions about chemotherapy affect the outcome of treatment in older women with newly diagnosed breast cancer.
- Detailed Description
OBJECTIVES:
* Determine the relationship between preferences and chemotherapy decisions in women age 65 and over with operable, newly diagnosed breast cancer.
* Determine how factors that could be targets for intervention affect the relationship between preferences and chemotherapy decisions in these patients.
* Determine the relationships between preference-based chemotherapy decisions, quality of life, and satisfaction with treatment decisions in these patients.
* Determine the disease-free survival and competing causes of mortality of these patients.
* Determine the types of physician providers who care for older breast cancer survivors after initial cancer treatment is completed and explore how women decide about which physicians to see.
* Measure quality indicators for the survivorship phase of care and evaluate if quality varies by type of physician provider model.
* Determine if long-term patient-reported satisfaction varies as a function of physician model for providing follow-up care post-treatment.
* Determine whether physician-patient communication and coordination of care after treatment ends mediate follow-up quality and outcomes post-treatment.
OUTLINE: This is a cohort study.
Patients participate in interviews over 30-45 minutes at baseline, at 6 months, and at 1 and 2 years.
Patients are followed annually for at least 5 years.
PROJECTED ACCRUAL: A total of 1,296 patients will be accrued for this study within 18-24 months.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 1706
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method quality of life Up to 5 years
- Secondary Outcome Measures
Name Time Method disease free survival Up to 5 years mortality rate Up to 5 years
Trial Locations
- Locations (84)
Camino Medical Group - Treatment Center
🇺🇸Mountain View, California, United States
Palo Alto Medical Foundation
🇺🇸Palo Alto, California, United States
Bendheim Cancer Center at Greenwich Hospital
🇺🇸Greenwich, Connecticut, United States
Washington Cancer Institute at Washington Hospital Center
🇺🇸Washington, D.C., District of Columbia, United States
Walter Reed Army Medical Center
🇺🇸Washington, D.C., District of Columbia, United States
Cancer Center of South Florida Foundation, Incorporated
🇺🇸Lake Worth, Florida, United States
University of Chicago Cancer Research Center
🇺🇸Chicago, Illinois, United States
Louis A. Weiss Memorial Hospital
🇺🇸Chicago, Illinois, United States
La Grange Memorial Hospital
🇺🇸La Grange, Illinois, United States
Center for Cancer Care at OSF Saint Anthony Medical Center
🇺🇸Rockford, Illinois, United States
Scroll for more (74 remaining)Camino Medical Group - Treatment Center🇺🇸Mountain View, California, United States